Palmitate induces human glomerular mesangial cells fibrosis through CD36-mediated transient receptor potential canonical channel 6/nuclear factor of activated T cell 2 activation

Author(s):  
Yong Su ◽  
Qingqing Chen ◽  
Yinghui Ju ◽  
Weizu Li ◽  
Weiping Li
Physiology ◽  
2005 ◽  
Vol 20 (2) ◽  
pp. 102-111 ◽  
Author(s):  
Rong Ma ◽  
Jennifer L. Pluznick ◽  
Steven C. Sansom

Ion channels in glomerular mesangial cells from humans, rats, and mice have been studied by electrophysiological, molecular, and gene-knockout methods. Two channels, a large, Ca2+-activated K+ channel (BK) and a store-operated Ca2+ channel (SOCC), can be defined with respect to molecular structure and function. Human BK, comprised of a pore-forming α-subunit and an accessory β1-subunit, operate as Ca2+-sensing feedback modulators of contractile tone. SOCC have also been characterized in a mouse cell line; they are comprised of molecules belonging to the transient receptor potential subfamily.


2021 ◽  
Author(s):  
Shouvonik Sengupta ◽  
Kelsi O. West ◽  
Shridhar Sanghvi ◽  
Georgios Laliotis ◽  
Laura M. Agosto ◽  
...  

AbstractProtein Arginine Methyltransferase (PRMT) 5 is the major type 2 methyltransferase catalyzing symmetric dimethylation (SDM) of arginine. PRMT5 inhibition or deletion in CD4 Th cells reduces TcR engagement-induced IL-2 production and Th cell expansion and confers protection against experimental autoimmune encephalomyelitis (EAE), the animal model of Multiple Sclerosis. However, the mechanisms by which PRMT5 modulates T helper (Th) cell proliferation are still not completely understood and neither are the methylation targets in T cells. In this manuscript, we uncover the role of PRMT5 on alternative splicing (AS) in activated T cells and identify several targets of PRMT5 SDM involved in splicing. In addition, we find a possible link between PRMT5 mediated AS of Trpm4 (Transient Receptor Potential Cation Channel Subfamily M Member 4) and TcR/NFAT signaling/IL-2 production. This understanding may guide development of drugs targeting these processes to benefit patients with T cell-mediated diseases.


Sign in / Sign up

Export Citation Format

Share Document